ClinicalTrials.gg
RecruitingNCT07330804HTAG-CORINUpdated Jan 9, 2026

STUDY OF THE DOUBLE POLYMORPHISM (THR 555ILE) AND (GLU568PRO) OF THE CORIN GENE AS A RISK FACTOR FOR ARTERIAL HYPERTENSION IN A POPULATION OF AFRICAN DESCENT IN GUADELOUPE

An interventional study of double polymorphism in High Blood Pressure, sponsored by Centre Hospitalier Universitaire de la Guadeloupe. Recruiting at 2 sites in Guadeloupe. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-09.

Sponsored by Centre Hospitalier Universitaire de la Guadeloupe · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Registered 3 months after the study started (first participant enrolled Jan 2025, registered Apr 2025).
  • Started Jan 2025; still recruiting 1 year 9 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
370
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Cardiovascular disease (CVD) mortality is the leading cause of death in high-income countries (particularly the United States), accounting for 23.1% of all deaths It has been established over several decades that hypertension disproportionately affects African Americans, compared with Americans of European descent:Hypertension occurs more often, at an earlier age , with greater severity , and is associated with an approximately 3-fold higher probability of death .There is also poorer control of hypertension despit e similar treatment In African Americans, CVD morbidity and mortality are compounded by the higher prevalence of T2DM, obesity, CKD, stroke, and heart failure . Despite advances in the identification of risk factors and the availability of effective treatment in hypertension, CVD disparities, persist among African Americans and are expected to increase in the future, particularly in younger age groups. Although various environmental and social factors certainly contribute to these disparities, a genetic basis, involving numerous "candidate" genes, is most often asserted in the literature . One of these is the Corin gene (Pan et al, 2002) which codes for the Corin protein.The latter plays a pivotal role in cardiometabolic pathophysiology through its role in the activation of natriuretic peptides .Natriuretic peptides (ANP and BNP) have a major role in the regulation of blood pressure through their vasodilatory and diuretic action. They have a lusotropic action, inhibit the renin angiotensin system, and are involved in energy metabolism (increased lipolysis and insulin secretion). They also have an anti-fibrotic, anti-proliferative, anti-inflammatory and anti-thrombotic action.The Corin gene of 244109pb has many variants that produce an inefficient protein with the corollary of the appearance of metabolic and cardiovascular pathologies in the first rank of which the HTA, the cardiac insufficiency and the renal insufficiency .Recently, a double polymorphism of the Corin gene consisting of 2 SNPs (single nucleotide polymorphisms) on the same allele of the Corin gene (I555/P568) has been reported. This allele is present in the heterozygous state in 12% of African Americans but is extremely rare in Americans of European descent (\<0.5%).This double polymorphism (I555/P568) has been shown to be responsible for an approximately 70% reduction in the ability of the mutated Corin protein to convert proANP or proBNP to the active form. In addition, the I555(P568) allele of Corin protein is associated with an increased risk of hypertension and concentric cardiac hypertrophy The corin allele (I555/P568) is reported to be associated with poorer response to validated heart failure therapy and a higher risk of death or hospitalization for heart failure .

In Guadeloupe, where the population is predominantly of African descent.Cardiovascular disease is the leading cause of mortality.The prevalence of hypertension is 39% and more than 50% after 50 years of age . It has increased by 10% in 10 years in Guadeloupe. In France, where the prevalence of hypertension is 31%, it has increased by only 5% over the same period.

Heart failure is the main cause of admission to the cardiological emergency room of the University Hospital (49%) with a mortality of 37% at 6 months. Hypertension is the first risk factor associated with heart failure (80%).To date, there are no studies on corin gene polymorphisms in Guadeloupe. Following the example of work already done in the African American population, we propose to study the role of the double polymorphism (I555/P568) in the determinism of hypertension in the population of African descent in Guadeloupe.

02

Conditions studied

  • High Blood Pressure

Browse trials for

Keywords

  • double polymorphisme
  • Corin
  • natriuretic peptide
  • biomarker
  • Afro Caribbean
03

In context

Hypertension

6,114 studies on the registry are indexed under Hypertension; 912 are open to participants now.

This study's planned enrollment of 370 is above the median of 100 across 4,575 interventional studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

Centre Hospitalier Universitaire de la Guadeloupe is the lead sponsor of 50 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Case inclusion criteria

  • Persons affiliated with or benefiting from a social security plan;
  • Over 18 years of age;
  • Considering themselves to be of Afro-Caribbean descent;
  • Having given their free, informed, written and signed consent (at the latest on the day of inclusion and before any examination required by the research);
  • Treated for hypertension or presenting with hypertension according to recommendations: elevated blood pressure (BP), including systolic blood pressure (SBP) ≥140 mmHg and/or diastolic blood pressure (DBP) ≥ 90 mmHg measured in the physician's office and confirmed over several visits on the day of inclusion or diagnosis made by ABPM or self-measurement.

Control inclusion criteria:

  • Individuals affiliated with or benefiting from a social security plan;
  • Over 18 years of age;
  • Patients who consider themselves of Afro-Caribbean origin, of the same sex as the cases and ± 5 years of age, not treated for hypertension and not presenting with hypertension according to the HAS recommendations on the day of the inclusion visit. Controls will be recruited by the same GPs who included a person with hypertension, consulting for any other symptom
  • Having given their free, informed, written and signed consent (at the latest on the day of inclusion and before any examination required by the research);

Exclusion criteria

Exclusion Criteria:

  • Minors; Pregnant or breastfeeding women; Protected persons, or persons under court protection; Refusal to participate. Patients unable to come to the laboratory
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
370 participants (estimated)

Study arms

  • Other
    cases

    Patients, considering themselves to be of Afro-Caribbean origin with hypertension, treated for hypertension or diagnosed as carrying hypertension according to HAS recommendations (Prise en charge de l'Hypertension artérielle de l'adulte, sept 2016): "elevation of blood pressure (BP), including systolic blood pressure (SBP) ≥140 mmHg and/or diastolic blood pressure (DBP) ≥ 90 mmHg" measured in the doctor's office and confirmed over several consultations on the day of inclusion. The diagnosis of hypertension can also be made by self-measurement over 3 days (mean PAS \>135 mmHg and/or PAS\> 85 mmHg) or by ABPM (Ambulatory Blood Pressure Monitoring: Holter Tensionnel) with PAS \>135 mmHg and/or PAD \>85 mmHg for the daytime period (awake); PAS\>120 mmHg and/or PAD\> 70 mmHg for the nighttime period (asleep). In the case of hypertension, mean PAS \> 130 mmHg and PAD \> 80 mmHg. ESC/ESH 2018 recommendations

    Diagnostic Test: double polymorphism

  • Other
    Controls

    Patients who consider themselves to be of Afro-Caribbean origin, of the same sex and ± 5 years of age as the cases, with no diagnosis of hypertension. Controls will be recruited by the same physicians who included a person with hypertension, but consulting for any other symptoms.

    Diagnostic Test: double polymorphism

Interventions

  • Diagnostic testdouble polymorphism

    diagnostic test

    Also known as: cases

06

What researchers measure

Primary outcomes

  1. double polymorphism

    1. Genotyping by capillary electrophoresis (Sanger sequencing): 2. Genotyping using the allelic discrimination method

    Time frame: At day 15

Secondary outcomes

  1. heart failure

    Frequency of heart failure in cases and controls

    Time frame: At inclusion

  2. Renal failure

    Frequency of renal failure in cases and

    Time frame: At Day 15

  3. natriuretic peptid (NT PRO BNP)

    natriuretic peptid assay in cases and controls

    Time frame: At Day 15

  4. créatinine clearance

    creatinine clearance in MDRD in cases and controls

    Time frame: At Day 15

  5. Fasting blood glucose

    Hb1AC measurement

    Time frame: At Day 15

  6. Cholesterolemia

    measurement

    Time frame: At Day 15

  7. triglyceridemia

    measurement

    Time frame: At Day 15

  8. Body Mass Index

    Body mass Index calculation measurement in cases and controls

    Time frame: At inclusion

  9. waist

    waist circumference measurement in cases and controls

    Time frame: At inclusion

  10. Left ventricular ejection fraction (LVEF)_systolic function in Simpson

    pourcentage

    Time frame: At 3 months for case, 12 months control

  11. ECG measurements Cornell

    mV

    Time frame: At inclusion, or month 3 for case and month 12 for control

  12. diastolic function E/ea ratio

    ratio

    Time frame: At inclusion, or month 3 for case and month 12 for control

  13. parietal thickness

    mm

    Time frame: At inclusion, or month 3 for case and month 12 for control

  14. left atrial size and volume

    ml

    Time frame: At inclusion, or month 3 for case and month 12 for control

  15. ECG measurement Lewis

    mV

    Time frame: At inclusion, or month 3 for case and month 12 for control

  16. ECG measurement Sokolow-Lyon

    mV

    Time frame: At inclusion, or month 3 for case and month 12 for control

  17. ECG measurment Siegel

    mV

    Time frame: At inclusion, or month 3 for case and month 12 for control

  18. ECG measurment Roberts

    mV

    Time frame: At inclusion, or month 3 for case and month 12 for control

07

Study locations

1 of 2 sites recruiting
  • Medical practice KERIB
    Petit-Bourg, 97170, Guadeloupe
    Recruiting
  • Toncoeurtonka
    Petit-Canal, 97131, Guadeloupe
    Not yet recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07330804
Lead sponsor
Centre Hospitalier Universitaire de la Guadeloupe
Responsible party
Sponsor
First posted
Jan 9, 2026
Start date
Jan 16, 2025
Primary completion
Aug 2026 (estimated)
Completion
Aug 2026 (estimated)
Last update
Jan 9, 2026

Study contacts

HEDREVILLE SEGO, Doctor
Contact
hedrevillesego.cabinet@orange.fr
+590 590 386355

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion